Pfizer exceeded 2025 financial expectations, reporting revenues of $62.6 billion and adjusted EPS of $3.22, driven by 6% operational growth in its non-COVID portfolio.
The company is executing a strategic pivot away from COVID-19 reliance, focusing on growth from recent acquisitions like Cigen, Metzera, and Biohaven, which generated $10.2 billion in 2025.
Pfizer is aggressively pursuing the potential $150 billion obesity market with its differentiated GLP-1 candidate, PF3944, highlighting promising data for a monthly dosing regimen with first approvals targeted for 2028.
The company is advancing a robust oncology pipeline, leveraging the Cigen acquisition to expand indications for drugs like PADCEF and develop next-generation antibody-drug conjugates (ADCs).
12 quotes
Concerns Raised
Significant revenue decline from COVID-19 products, which fell 40% in Q4.
Anticipated revenue compression from generic entry for key products.
Upcoming patent loss for Vindical at the end of 2028.
Opportunities Identified
Capturing a significant share of the potential $150 billion obesity market with a differentiated monthly-dosed GLP-1.
Label expansion for PADCEF in bladder cancer, potentially adding 22,500 U.S. patients.
Leveraging the robust oncology pipeline from the Cigen acquisition for long-term growth.
Utilizing $7 billion in business development capacity for further bolt-on acquisitions.